NVSNovartis PharmaceuticalsRunning, no new patients
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Metastatic Castration Resistant Prostate Cancer (mCRPC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 7 (final count)
- Started
- Sep 11, 2025
- Main results expected
- Oct 15, 2026
- Fully finished
- Oct 15, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: up to end of study, approx. 1.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06894511 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC